Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
Afexa Life Sciences Inc
ClinicalTrials.gov Identifier:
NCT01456182
First received: October 18, 2011
Last updated: January 23, 2012
Last verified: January 2012

October 18, 2011
January 23, 2012
December 2011
March 2013   (final data collection date for primary outcome measure)
  • Safety and tolerability will be assessed based on the incidence, duration and intensity of adverse events [ Time Frame: 0-8 weeks ] [ Designated as safety issue: Yes ]
    Adverse events will be graded according to NCI-CTC v4.
  • Safety and tolerability will also be determined by assessing any changes in study test results from baseline values [ Time Frame: 1 week, 4 weeks, 8 weeks ] [ Designated as safety issue: Yes ]
    Study tests that will determine safety include vital signs, clinical laboratory tests (hematology, serum chemistries, coagulation, urinalysis) and 12-lead EKG
Same as current
Complete list of historical versions of study NCT01456182 on ClinicalTrials.gov Archive Site
  • Quality of life indices [ Time Frame: 1 week, 4 weeks, 8 weeks ] [ Designated as safety issue: No ]
  • Maximum tolerated dose and/or dose-limiting toxicity [ Time Frame: 1 week, 4 weeks, 8 weeks ] [ Designated as safety issue: Yes ]
  • Biological and immune responses [ Time Frame: 1 week, 4 weeks, 8 weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia
Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia

This trial will assess the tolerability and safety of AFX-2 over a range of five dose levels in adults with low-, intermediate- or high-risk Chronic Lymphocytic Leukemia (CLL). The trial will also determine the impact of dose on quality of life indices and on biological and immune responses, and will assess if there is a maximum tolerated dose and/or dose-limiting toxicity in this study population.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Leukemia, Lymphocytic, Chronic, B-Cell
  • Drug: AFX-2
    Dose level 1
  • Drug: AFX-2
    Dose level 2
  • Drug: AFX-2
    Dose level 3
  • Drug: AFX-2
    Dose level 4
  • Drug: AFX-2
    Dose level 5
  • Dose arm 1
    Intervention: Drug: AFX-2
  • Dose arm 2
    Intervention: Drug: AFX-2
  • Dose arm 3
    Intervention: Drug: AFX-2
  • Dose arm 4
    Intervention: Drug: AFX-2
  • Dose arm 5
    Intervention: Drug: AFX-2
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
May 2013
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Adult men and women >18 years of age
  2. Diagnosis of CLL per NCI Working Group Criteria; with phenotypic evidence (i.e.. flow cytometry or bone marrow biopsy) of chronic lymphocytic leukemia (MEDDRA Code - 10008960; ICD-O3-9823)
  3. Disease meets criteria for low-risk (Rai Stage 0), intermediate-risk (Rai Stage I- II), or high-risk (Rai Stage III-IV) disease
  4. Life expectancy of ≥ 3 months at Screening.
  5. ECOG performance status 0-3
  6. Laboratory parameters (taken < 14 days of Study Day 0):

    • Hematologic parameters: Hemoglobin > 9 gm/dL (stable, not dropping); Absolute Granulocyte Count (AGC) > 1.0 x 109/L; Platelets > 50 x 109/L; not requiring immediate transfusion.
    • Coagulation: PT/PTT/INR: ± 10% of NL for lab; INR: 1.0-1.43
    • BUN < 40; serum Creatinine ≤ 2.0 mg/dL, OR Creatinine Clearance > 90 mL/min/1.73m2 IF serum Creatinine > 2.0 mg/dL
    • Liver function tests (AST, ALT, ALP, LDH): < 2.5 x institutional ULN; Total bilirubin: < 2.0 x institutional ULN
    • Human Immunodeficiency Virus (HIV) negative
    • Pregnancy test: negative urine pregnancy test for females of child-bearing potential,
  7. Free of disease from prior malignancy/ies for > 2 years, except for basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast.
  8. If not surgically sterile, or post-menopausal (> 12 months with no menstrual flow), willing to practice birth control (barrier + contraception) throughout duration of study.
  9. Able and willing to swallow capsules.
  10. Willing to limit alcohol intake during the study treatment period.
  11. Willing to sign the informed consent.

Exclusion Criteria:

  1. Lymphoproliferative disease other than CLL
  2. Prior use of the test article (AFX-2), or ginseng-containing products (American, Asian, etc.) ≤ 1 year prior to study entry.
  3. Known allergy to the test article or ginseng-containing products
  4. Active infection requiring systemic treatment
  5. Prior or current therapy:

    • Splenectomy.
    • Currently requiring anticoagulant therapy
    • Requiring active treatment for B-CLL or ≤ 28 days post-treatment for B-CLL or other condition requiring: chemotherapy, radiation therapy, monoclonal antibodies, systemic steroids, antihistamines or non-steroidal anti-inflammatory drugs, including ibuprofen, indomethacin, COX-2 inhibitors etc.
    • ≤ 10 days: non-steroidal hormonal therapy (other than for contraception or thyroid)
    • ≤ 10 days: antibiotic prophylaxis
    • History of therapy with immunological reagents, such as allogeneic bone marrow transplant, monoclonal antibody therapy, intravenous immunoglobulin, or hematopoietic stem cell transplantation. (Note: Immunotherapy for allergies is permitted as long as the last treatment was both (a) prior to the CLL diagnosis and (b) > 5 years prior to trial enrollment.)
    • < 90 days post treatment with chlorambucil
    • < 90 days post general anesthesia
  6. Uncontrolled intercurrent condition, including, but not limited to, cardiovascular, pulmonary, renal, hepatic, GI, GU, neurologic, metabolic, psychiatric, etc.
  7. Current or prior investigational product or procedure < 56 days preceding study entry (Baseline -Visit 2; Study Day 0).
  8. Unwilling to discontinue use of nonprescription (OTC), nutritional or dietary supplements during the study period (as further defined by protocol).
  9. Pregnant, lactating.
  10. Any condition, personal or social situation that precludes or limits the ability of the participant to provide informed consent or comply with study requirements.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01456182
AFX-2-2010-1
No
Afexa Life Sciences Inc
Afexa Life Sciences Inc
Not Provided
Principal Investigator: Leslie R Ellis, MD Wake Forest University Health Sciences Center
Afexa Life Sciences Inc
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP